Sentences with phrase «pharmacogenomic study»

Dr Dan Hawcutt, Senior Lecturer Paediatric Clinical Pharmacology University of Liverpool and Honorary Consultant Paediatrician Alder Hey Children's Hospital, said: «This is the first pharmacogenomic study investigating the association between a patient's genotype and corticosteroid induced adrenal suppression.

Not exact matches

I continued working at the interface of science and epidemiology, first with Genaissance Pharmaceuticals, a New Haven - based pharmacogenomics company, where I was involved in the fascinating study of human genetic variation and population genetics.

That's why some AD researchers are turning to pharmacogenomics: the study of how genes influence the way we respond to drugs.

As a member of their scientific advisory boards, he helps the study directors design the pharmacogenomic portion of new clinical drug trials.

One current study looks at the pharmacogenomic profile of asthma patients and healthy controls, and these data will serve as a reference database for future studies.

Pharmacogenomics — the study of how genes affect responses to drugs — is becoming more important in drug - development research and clinical trials, with a view toward decreasing side effects and increasing the efficiency and efficacy of drugs in patients with the right genetic profiles.

Furthermore, results of this study provide essential directions to future pharmacogenomic research for reduction of ADR - related hospitalizations in Singapore,» said Professor Alexandre Chan, co-senior author of the British Journal of Clinical Pharmacology study.

A recent study of a new course in pharmacogenomics at Washington State University Spokane found the class expanded students» understanding of these possibilities for their profession.

Also, reference is made to the concept of measurable efficacy in personalized medicine, while detailed examples and standard economic assessment studies in pharmacogenomics and personalized medicine are discussed.

Results of this study has shown that there is a significant inter-population variability, as far as pharmacogenomic biomarker allele frequency is concerned, which has a direct impact on the rationalization of drug use at a population level.

Pharmacogenomics, the study of how an individual's genetic variations impact the response to drugs, has emerged as an essential tool to optimize therapy and minimize the risk of adverse effects.

Pharmacogenomics: Pharmacogenomics is the study of how a person's genetic makeup affects how medications and medication doses are likely to work best for a particular person or which individuals are more likely to suffer adverse consequences.

This section invites manuscripts describing (a) Linkage, association, substitution or positional mapping and epigenetic studies in any species; (b) Validation studies of candidate genes using genetically - engineered mutant model organisms; (c) Studies focused on epistatis and gene - environment interactions; (d) Analysis of the functional implications of genomic sequence variation and aim to attach physiological or pharmacogenomic relevance to alterations in genes or proteins; (e) Studies of DNA copy number variants, non-coding RNA, genome deletions, insertions, duplications and other single nucleotide polymorphisms and their relevance to physiology or pharmacology in humans or model organisms, in vitro or in vivo; and (f) Theoretical approaches to analysis of sequence varstudies in any species; (b) Validation studies of candidate genes using genetically - engineered mutant model organisms; (c) Studies focused on epistatis and gene - environment interactions; (d) Analysis of the functional implications of genomic sequence variation and aim to attach physiological or pharmacogenomic relevance to alterations in genes or proteins; (e) Studies of DNA copy number variants, non-coding RNA, genome deletions, insertions, duplications and other single nucleotide polymorphisms and their relevance to physiology or pharmacology in humans or model organisms, in vitro or in vivo; and (f) Theoretical approaches to analysis of sequence varstudies of candidate genes using genetically - engineered mutant model organisms; (c) Studies focused on epistatis and gene - environment interactions; (d) Analysis of the functional implications of genomic sequence variation and aim to attach physiological or pharmacogenomic relevance to alterations in genes or proteins; (e) Studies of DNA copy number variants, non-coding RNA, genome deletions, insertions, duplications and other single nucleotide polymorphisms and their relevance to physiology or pharmacology in humans or model organisms, in vitro or in vivo; and (f) Theoretical approaches to analysis of sequence varStudies focused on epistatis and gene - environment interactions; (d) Analysis of the functional implications of genomic sequence variation and aim to attach physiological or pharmacogenomic relevance to alterations in genes or proteins; (e) Studies of DNA copy number variants, non-coding RNA, genome deletions, insertions, duplications and other single nucleotide polymorphisms and their relevance to physiology or pharmacology in humans or model organisms, in vitro or in vivo; and (f) Theoretical approaches to analysis of sequence varStudies of DNA copy number variants, non-coding RNA, genome deletions, insertions, duplications and other single nucleotide polymorphisms and their relevance to physiology or pharmacology in humans or model organisms, in vitro or in vivo; and (f) Theoretical approaches to analysis of sequence variation.

«From the 15,000 fold drop in the cost of DNA sequencing to the increasing use of personalized medicine and pharmacogenomics, this study demonstrates that the human genome project has indeed been transformative.»

The study reported just 12.6 percent of physicians were extremely or very familiar with pharmacogenomics.